Selinexor not checked

Karyopharm Therapeutics Inc · KCP-330 · ATG-010

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
12 active
42 in total · 12 in the EU
Targets
 

What this is

How it works
Nuclear Export Inhibitor FDA class
How it’s given
“Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.”In the company’s words, NCT04562389 on ClinicalTrials.gov
Tested for
Myelofibrosis (3 trials), Endometrial Cancer, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Moderate Thrombocytopenia, Mild Thrombocytopenia, Multiple Myeloma, Refractory, Multiple Myeloma
Main trialPhase 3
“This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of…”In the company’s words, NCT04562389 on ClinicalTrials.gov
Other names
KCP-330 · ATG-010 · Xpovio · KPT-330

Other drugs for Myelofibrosis

All 37 drugs for Myelofibrosis

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials42

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 20 Feb 2026 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Phase 3Active, not recruiting 22 May 2026 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Phase 2/3Active, not recruiting Dec 2026 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2Active, not recruiting Sep 2026 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Phase 2Active, not recruiting Dec 2026 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Recruiting Jun 2027 A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Phase 2Recruiting Jan 2028 A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Phase 1/2Recruiting Apr 2027 Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 3Completed 18 Feb 2020 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Phase 3Completed 22 Jan 2022 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Phase 2/3Completed 28 Oct 2020 Selinexor in Advanced Liposarcoma
Phase 2Terminated 10 Dec 2015 Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Phase 2Terminated Jan 2016 Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Phase 2Terminated 1 Apr 2016 SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
Phase 2Terminated 31 Aug 2016 Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
Phase 2Completed 24 Jan 2017 Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
Phase 2Withdrawn Jun 2017 Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Phase 2Withdrawn Dec 2017 Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Phase 2Completed 8 Jan 2018 Selinexor (KPT-330) in Older Patients With Relapsed AML
Phase 2Completed 26 Jul 2019 Selinexor Treatment of Refractory Myeloma
Phase 2Terminated 23 Jan 2020 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
Phase 2Withdrawn 30 Aug 2020 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
Phase 2Completed 5 Oct 2020 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Phase 2Completed 25 Feb 2022 A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
Phase 2Terminated 24 Jun 2022 A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Phase 2Completed 31 May 2023 A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2Terminated 22 Sep 2023 Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Phase 1/2Withdrawn May 2015 Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
Phase 1/2Withdrawn Jan 2018 Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Phase 1/2Terminated 3 Jul 2023 A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Phase 1/2Completed 31 Jul 2024 Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Phase 1/2Terminated 31 Dec 2024 A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
Phase 1/2Withdrawn Dec 2025 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1Completed 13 Oct 2015 Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1Completed 15 Mar 2016 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1Completed 21 Oct 2016 A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Phase 1Terminated 6 Feb 2023 A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2Authorised not given Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial
Phase 2Authorised not given Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas
Phase 1/2Not authorised not given Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas
Phase 3Authorised not given A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase 1/2Authorised not given Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Selinexor

Following is part of Solo: you see every change to Selinexor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in